quinazoline-2-carboxamide | 501692-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: quinazoline-2-carboxamide
• 英文别名: quinazoline carboxamide；quinazoline amide
• CAS: 501692-64-4
• 化学式: C₉H₇N₃O
• 分子量: 173.174
• InChiKey: ABVYZAMNSCVWJA-UHFFFAOYSA-N

物化性质

• 熔点：
  198 °C
• 沸点：
  418.9±28.0 °C(Predicted)
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  喹唑啉 、 formamide 在 N-羟基邻苯二甲酰亚胺 、 ammonium cerium(IV) nitrate 、 三氟乙酸 作用下， 反应 6.0h， 生成 quinazoline-2-carboxamide
  参考文献：
  名称：

  A novel, selective free-radical carbamoylation of heteroaromatic bases by Ce(iv) oxidation of formamide, catalysed by N-hydroxyphthalimide

  摘要：

  Ce(IV)-NHPI 系统通过甲酰胺氧化生成氨基甲酰基；这种亲核自由基已成功用于杂芳基的氨基甲酰化。

  DOI：

  10.1039/b206192a

文献信息

• HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
  申请人：Bertin Luc

  公开号：US20120010241A1

  公开（公告）日：2012-01-12

  The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R′1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A′), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs.

  本发明涉及具有公式(I)的新产品，其中：R4代表H，CH3，CH2CH3，CF3，F，Cl，Br，I；Het代表一个杂环，可选地由一个或多个R1或R'1自由基取代，这些自由基选自H，卤素，CF3，硝基，腈基，烷基，羟基，巯基，氨基，烷基氨基，二烷基氨基，烷氧基，苯基烷氧基，烷基硫醚，游离或与烷基自由基酯化的羧基，羧酰胺，CO—NH(烷基)，CON(烷基)2，NH—CO-烷基，磺酰胺，NH—SO2-烷基，S(O)2-NH烷基，S(O2)-N(烷基)2，所有烷基，烷氧基和烷基硫醚自由基都是可选取代的；R选自包括(A′)，(B)，(C)，(D)和(F)的组，其中W1，W2，W3独立代表CH或N，X代表O，S，NR2，C(O)，S(O)或S(O)2；V代表H，Hal，—O—R2或—NH—R2，R2代表H，烷基，环烷基或杂环烷基，可选取代；所述产品为所有异构体形式，以及盐，用于作为药物使用。
• PHENYLQUINAZOLINE DERIVATIVES
  申请人：Eggenweiler Hans-Michael

  公开号：US20130178443A1

  公开（公告）日：2013-07-11

  Novel quinazolinamide derivatives of the formula (I), in which R1-R43 and X have the meanings indicated in claim 1 , are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  化合物(I)的新型喹唑啉酰胺衍生物，其中R1-R43和X具有权利要求书中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90在疾病的抑制、调节和/或调控中发挥作用的药物。
• QUINAZOLINE DERIVATIVES
  申请人：Eggenweiler Hans Michael

  公开号：US20120238582A1

  公开（公告）日：2012-09-20

  Novel quinazolinamide derivatives of the formula (I), in which R 1 -R 4 and X have the meanings indicated in Claim 1 , are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  式（I）中的新型喹唑啉酰胺衍生物，其中R1-R4和X具有权利要求书中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90起作用的疾病的药物。
• Quinazolinamide derivatives
  申请人：Eggenweiler Hans-Michael

  公开号：US20100234324A1

  公开（公告）日：2010-09-16

  Novel quinazolinamide derivatives of the formula (I), in which R 1 -R 3 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  新型喹唑啉酰胺衍生物的化学式（I），其中R1-R3具有权利要求书中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90在疾病的抑制、调节和/或调控中发挥作用的药物。
• [EN] SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MÉTALLOPROTÉINASES-13 MATRICIELLES
  申请人：FLORIDA ATLANTIC UNIV BOARD OF TRUSTEES

  公开号：WO2018226837A1

  公开（公告）日：2018-12-13

  We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting with a comparative analysis of the X-ray crystallographic structure of compound 5 in complex with MMP-13 with published structures of known MMP-13inhibitor complexes followed by molecular design and synthesis of potent, but non-selective zinc-chelating MMP inhibitors (e.g., 10a and 10b). After demonstrating that the pharmacophores of the chelating inhibitors (S)-10a, (R)-10a, and 10b were binding within the MMP-13 active site, the Zn2+ chelating unit was replaced with non-chelating polar residues that bridged over the Zn2+ binding site and reach into a solvent accessible area. After two rounds of structural optimization, these design approaches led to small molecule MMP-13 inhibitors 10d and (S)-17b which bind within the substrate-binding site of MMP-13 and surround the catalytically active Zn2+ ion without chelating to the metal. These compounds exhibit at least 500-fold selectivity versus other MMPs.

  我们描述了比较结构分析和结构引导的分子设计的使用，以开发针对基质金属蛋白酶13（MMP-13）的有效且选择性抑制剂（10d和（S）-17b）。我们应用了一个三步过程，首先是对化合物5与MMP-13复合物的X射线晶体结构进行比较分析，然后与已知的MMP-13抑制剂复合物的已发表结构进行比较，接着进行分子设计和合成有效但非选择性的锌螯合MMP抑制剂（例如10a和10b）。在证明了螯合抑制剂（S）-10a、（R）-10a和10b的药效团结合在MMP-13活性位点内后，Zn2+螯合单元被替换为桥接到Zn2+结合位点并伸入溶剂可接触区域的非螯合极性残基。经过两轮结构优化，这些设计方法导致小分子MMP-13抑制剂10d和（S）-17b，它们结合在MMP-13的底物结合位点，并围绕着催化活性的Zn2+离子，而不与金属螯合。这些化合物与其他MMP至少具有500倍的选择性。